RSS
Pieris Appoints a New CEO / Appointment will bring substantial deal-making expertise to the company
Freising-Weihenstephan, Germany (ots) - Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr. ... weiter zur Meldung von Pieris AG
Pieris reports preclinical development progress of its next generation VEGF antagonist / PRS-050 program on track to commence clinical trials as planned
Freising-Weihenstephan, Germany (ots) - Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program ... weiter zur Meldung von Pieris AG
Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
Freising-Weihenstephan, Germany (ots) - Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug ... weiter zur Meldung von Pieris AG
Pieris reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist / Expansion of management team announced to support program success
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its ... weiter zur Meldung von Pieris AG
WACKER bestätigt Skalierbarkeit der Anticalin®-Produktion mit der E.coli-Sekretionstechnologie und wird den ersten klinischen Kandidaten von Pieris PRS-050 herstellen
Freising-Weihenstephan/Jena (ots) - Die Pieris AG, ein biopharmazeutisches Unternehmen spezialisiert auf die Entwicklung von Anticalinen®, einer neuen Klasse von Wirkstoffen aus maßgeschneiderten humanen Bindeproteinen, und die Wacker Biotech ... weiter zur Meldung von Pieris AG
Pieris raises EUR 25 M (US$ 38 M) in Series B financing round / New investment round led by OrbiMed Advisors, world?s largest healthcare investment firm
Freising-Weihenstephan, Germany (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor ... weiter zur Meldung von Pieris AG
Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin®-based novel cancer therapy
Freising-Weihenstephan (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced the appointment of Dr Angelika Stern as Chief Operating Officer to the Company. ... weiter zur Meldung von Pieris AG
Pieris and Pepscan to identify GPCR-specific Anticalins® using CLIPS[TM] protein mimicry technology
Freising (ots) - Pieris AG (Munich, Germany) and Pepscan Therapeutics (Lelystad, Netherlands) today announced the commencement of a research collaboration aimed at identifying Anticalins® specific for G-Protein Coupled Receptors (GPCRs) and ... weiter zur Meldung von Pieris AG
Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating ... weiter zur Meldung von Pieris AG
Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin®-based protein product candidate
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for ... weiter zur Meldung von Pieris AG
Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully ... weiter zur Meldung von Pieris AG
Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin® in preclinical studies
Freising-Weihenstephan, Germany (ots) - Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin® in preclinical studies Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of ... weiter zur Meldung von Pieris AG
Pieris confirms in vivo activity of potent VEGF-specific Anticalin®
Freising-Weihenstephan, Germany - (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today that it has confirmed the functional ... weiter zur Meldung von Pieris AG
Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics
Freising-Weihenstephan/Germany (ots) - Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics Pieris AG, a biopharmaceutical ... weiter zur Meldung von Pieris AG
Pieris reaches key milestones under the collaboration agreement with Syngenta
Freising-Weihenstephan, Germany (ots) - July 6th 2006. Pieris AG, a biopharmaceutical and protein engineering company exploiting its proprietary Anticalin® technology for the development of superior human biotherapeutic and diagnostics products, ... weiter zur Meldung von Pieris AG
Pieris appoints new Chief Executive Officer
Freising-Weihenstephan, Germany (ots) - Pieris Proteolab AG announced today the appointment with immediate effect of Evert Küppers (37) as its new Chief Executive Officer. Mr Küppers joins Pieris from IDEA AG, where he was Vice President and ... weiter zur Meldung von Pieris AG
Pieris enters into a collaborative research and option agreement with GE Healthcare
Freising-Weihenstephan, Germany (ots) - Pieris Proteolab AG and GE Healthcare today announced that they have entered into a research collaboration for the discovery of novel targeted in vivo diagnostic and medical imaging compounds, a technology ... weiter zur Meldung von Pieris AG
